These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 37469254

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
    Jiang W, He T, Liu S, Zheng Y, Xiang L, Pei X, Wang Z, Yang H.
    J Hematol Oncol; 2018 Dec 14; 11(1):139. PubMed ID: 30547809
    [Abstract] [Full Text] [Related]

  • 5. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
    Song L, Liu S, Zhao S.
    Bioengineered; 2022 Apr 14; 13(4):11240-11257. PubMed ID: 35485300
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
    Bräutigam K, Schmidt T, Baur M, Tauber N, Kontomanolis EN, Hemptenmacher F, Rody A, Köster F.
    Anticancer Res; 2024 Feb 14; 44(2):503-510. PubMed ID: 38307554
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
    Krishnamurthy S, Yoda H, Hiraoka K, Inoue T, Lin J, Shinozaki Y, Watanabe T, Koshikawa N, Takatori A, Nagase H.
    Cancer Sci; 2021 Mar 14; 112(3):1141-1149. PubMed ID: 33377228
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Kim HJ, Lee SY, Kim CY, Kim YH, Ju W, Kim SC.
    Oncotarget; 2017 Jan 24; 8(4):6608-6622. PubMed ID: 28036259
    [Abstract] [Full Text] [Related]

  • 13. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
    Wang D, Wu S, He J, Sun L, Zhu H, Zhang Y, Liu S, Duan X, Wang Y, Xu T.
    J Exp Clin Cancer Res; 2023 Sep 01; 42(1):222. PubMed ID: 37658376
    [Abstract] [Full Text] [Related]

  • 14. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y, Zhang XL, Liu ZX, Zhao JJ, Pan QZ, Wen XZ, Xiao W, Xu BS, Hong DC, Guo TH, Shen LJ, Fan WJ, Chen HY, Weng DS, Xu HR, Zhou PH, Zhang YZ, Niu XH, Zhang X.
    J Immunother Cancer; 2021 Feb 01; 9(2):. PubMed ID: 33637599
    [Abstract] [Full Text] [Related]

  • 15. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F, Alejandre-Gonzalez AG, Ortiz-Lazareno PC, Bastidas-Ramirez BE, Zepeda-Moreno A, Tellez-Bañuelos MC, Banu N, Carrillo-Garibaldi OJ, Chavira-Alvarado A, Bueno-Topete MR, Del Toro-Arreola S, Haramati J.
    Clin Exp Immunol; 2021 Apr 01; 204(1):78-95. PubMed ID: 33306195
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer.
    Jiang W, Ouyang X, Ji Z, Shi W, Wu Y, Yao Q, Wang Y, Yang W, Xiang L, Yang H.
    Cancer Lett; 2023 Mar 01; 556():216064. PubMed ID: 36646410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.